Certara, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Certara, Inc. agreed on April 21, 2026 to sell its regulatory services business (medical writing, clinical documentation, regulatory operations) to Veristat Parent LP and affiliates for a base Closing Purchase Price of $100 million (subject to working capital and other adjustments), plus potential earnout and trigger deferred payments. The deal includes equity interests in four companies and substantial transferred assets/liabilities, with closing targeted for June 2026 and earnout period through end of 2026.
Why this rating
Transaction is ~7% of Certara's $1.4B market cap. Material divestiture but company retains other businesses (CoAuthor, GlobalSubmit, Philippines ops). Deal structure with earnout/deferred payments and multiple closing conditions creates execution risk but is ordinary corporate M&A.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.